Duncker Streett & Co. Inc. Has $607,000 Position in Laboratory Co. of America Holdings (NYSE:LH)

Duncker Streett & Co. Inc. boosted its position in shares of Laboratory Co. of America Holdings (NYSE:LH) by 3.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,645 shares of the medical research company’s stock after purchasing an additional 98 shares during the quarter. Duncker Streett & Co. Inc.’s holdings in Laboratory Co. of America were worth $607,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Private Trust Co. NA raised its position in shares of Laboratory Co. of America by 3.2% in the third quarter. Private Trust Co. NA now owns 1,342 shares of the medical research company’s stock valued at $300,000 after purchasing an additional 41 shares during the period. Empowered Funds LLC raised its position in shares of Laboratory Co. of America by 0.5% in the fourth quarter. Empowered Funds LLC now owns 8,025 shares of the medical research company’s stock valued at $1,840,000 after purchasing an additional 43 shares during the period. Oppenheimer Asset Management Inc. raised its position in shares of Laboratory Co. of America by 0.4% in the fourth quarter. Oppenheimer Asset Management Inc. now owns 12,780 shares of the medical research company’s stock valued at $2,931,000 after purchasing an additional 45 shares during the period. Oregon Public Employees Retirement Fund raised its position in shares of Laboratory Co. of America by 0.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 7,194 shares of the medical research company’s stock valued at $1,650,000 after purchasing an additional 46 shares during the period. Finally, Empirical Finance LLC raised its position in shares of Laboratory Co. of America by 1.7% in the third quarter. Empirical Finance LLC now owns 3,055 shares of the medical research company’s stock valued at $683,000 after purchasing an additional 50 shares during the period. Institutional investors and hedge funds own 95.94% of the company’s stock.

Insider Transactions at Laboratory Co. of America

In related news, EVP Der Vaart Sandra D. Van sold 1,314 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $251.30, for a total value of $330,208.20. Following the completion of the transaction, the executive vice president now owns 2,171 shares in the company, valued at $545,572.30. This trade represents a 37.70 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Amy B. Summy sold 226 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $250.40, for a total transaction of $56,590.40. Following the transaction, the chief marketing officer now owns 4,544 shares of the company’s stock, valued at approximately $1,137,817.60. The trade was a 4.74 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 21,372 shares of company stock valued at $5,175,793. 0.85% of the stock is currently owned by insiders.

Laboratory Co. of America Trading Up 1.5 %

Shares of Laboratory Co. of America stock opened at $251.45 on Friday. The company has a market capitalization of $21.03 billion, a price-to-earnings ratio of 28.51, a PEG ratio of 1.71 and a beta of 1.07. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.67. Laboratory Co. of America Holdings has a 12-month low of $191.97 and a 12-month high of $258.59. The firm’s 50-day moving average price is $241.20 and its two-hundred day moving average price is $232.70.

Laboratory Co. of America (NYSE:LH) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. On average, analysts forecast that Laboratory Co. of America Holdings will post 16.01 earnings per share for the current fiscal year.

Laboratory Co. of America Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th will be issued a $0.72 dividend. The ex-dividend date of this dividend is Thursday, February 27th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.15%. Laboratory Co. of America’s dividend payout ratio (DPR) is currently 32.65%.

Analysts Set New Price Targets

Several brokerages have recently weighed in on LH. UBS Group dropped their price objective on shares of Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Piper Sandler increased their price objective on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Bank of America increased their price objective on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Jefferies Financial Group upped their price target on shares of Laboratory Co. of America from $275.00 to $290.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. Finally, Morgan Stanley upped their price target on shares of Laboratory Co. of America from $260.00 to $270.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $265.75.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.